Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025

Rhea-AI Summary

Profusa (Nasdaq: PFSA) announced acceptance of a Late Breaking Clinical Trial Update presentation at Paris Vascular Insights 2025, Dec 11-13, 2025, in Paris.

The presentation, by Peter Schneider, M.D., is titled "Monitoring Tissue Oxygen Dynamics with a Novel Implantable Hydrogel Sensor in Patients with Peripheral Arterial Disease (PAD)" and is scheduled for Dec 13, 2025, 13:00–13:40 CET at Carrousel du Louvre. The update covers a U.S.-based clinical study of the Lumee oxygen tissue monitoring platform using transcutaneous partial pressure of oxygen (tcpO2) to measure continuous, real-time tissue oxygen dynamics.

Insights

Vascular clinical-trial analyst

Late-breaking presentation signals clinical progress for the Lumee tcpO2 study, but no outcome data are disclosed yet.

Profusa secured a late-breaking oral slot at Paris Vascular Insights on December 11-13, 2025, with a focused presentation scheduled on December 13, 2025. The session highlights the company’s U.S.-based study of the Lumee implantable hydrogel sensor measuring transcutaneous partial pressure of oxygen (tcpO2) in peripheral artery disease patients, which confirms continued trial activity and visibility within the vascular surgery community.

The business mechanism is straightforward: clinical visibility and peer presentation increase scientific credibility and may support regulatory or commercial conversations, but the announcement contains no efficacy, safety, enrollment, or endpoint data. Key dependencies and risks remain unchanged because no data are disclosed; clinical, regulatory, or commercial impact depends entirely on the unpublished trial results and any regulatory submissions that follow.

Watch for the actual presentation content on December 13, 2025 (1:00pm CET) and any accompanying slides, abstracts, or peer-reviewed manuscripts that specify primary endpoints, sample size, and safety findings. Near-term signals to monitor are enrollment completeness, primary endpoint status, and adverse event summaries reported at the session or in an abstract; these items determine material investor relevance within weeks after the presentation.

Study evaluates Lumee™ Oxygen tissue monitoring platform with transcutaneous partial pressure of oxygen (tcpO₂) in peripheral artery disease patients

BERKELEY, Calif, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, announces the acceptance of an abstract for a Late Breaking Clinical Trial Update presentation at the upcoming Paris Vascular Insights (PVI) 2025, being held on December 11-13, 2025, in Paris, France.

Presentation:

Title	Monitoring Tissue Oxygen Dynamics with a Novel Implantable Hydrogel Sensor in Patients with Peripheral Arterial Disease (PAD)
Presenter	Peter Schneider, M.D., Professor of Surgery, Division of Vascular & Endovascular Surgery, Department of Surgery, School of Medicine, University of California, San Francisco
Date/Time	Saturday, December 13, 2025, 1pm to 1:40 pm CET (Central European Time)
Location	Carrousel du Louvre

“Our Lumee oxygen tissue monitoring technology enables continuous, real-time measurement of tissue oxygen directly within the body, a first-of-its-kind, disruptive biochemistry monitoring platform designed for use both in the clinic and at home,” said Ben Hwang, Ph.D., Profusa’s Chairman and CEO. “We are excited to present an update on our U.S.-based clinical study evaluating our pioneering Lumee technology with tcpO₂ at the late breaking session at PVI, a global vascular community gathering pushing the boundaries of innovation to shape the future of vascular and endovascular surgery.”

About Profusa

Based in Berkeley, Calif., Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.

“LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia.

For more information, visit https://profusa.com.

Special Note Regarding Forward-Looking Statements

Certain statements in this press release (this “Press Release”) may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described in the definitive proxy/final prospectus relating to the business combination, which has been filed with the SEC, and in other documents filed by Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.

Contacts

Investor and Media Contacts
email:  info@coreir.com
phone:  1 (212) 655-0924

FAQ

What will Profusa (PFSA) present at Paris Vascular Insights 2025 on Dec 13, 2025?

Profusa will present a Late Breaking Clinical Trial Update titled "Monitoring Tissue Oxygen Dynamics with a Novel Implantable Hydrogel Sensor in PAD" on Dec 13, 2025, 13:00–13:40 CET.

Who is presenting Profusa's Late Breaking Clinical Trial Update for PFSA at PVI 2025?

The presentation will be delivered by Peter Schneider, M.D., Professor of Surgery, UCSF.

What technology is Profusa (PFSA) updating at the PVI 2025 late breaking session?

The update covers the Lumee oxygen tissue monitoring platform using implantable hydrogel sensors and tcpO2 to monitor tissue oxygen in PAD patients.

When and where is Profusa's PFSA presentation taking place at PVI 2025?

The presentation is on Saturday, Dec 13, 2025, 13:00–13:40 CET at the Carrousel du Louvre in Paris.

Is Profusa's PFSA study clinical or preclinical and which patient group is included?

The announcement describes a U.S.-based clinical study evaluating the technology in patients with peripheral arterial disease (PAD).

What measurement does Profusa's Lumee system use in the PFSA clinical study?

The Lumee system in the study is evaluated using transcutaneous partial pressure of oxygen (tcpO2) to assess tissue oxygen dynamics.